Labiotech.eu

News and Trends 5 Oct 2017

Synbio adds Softness: Robots of the Future will be Squishy

As AI and machine learning approach biotech, synthetic biology is approaching soft robotics. What is it bringing to the field? Conventional rigid-bodied robots are used to perform specific single tasks efficiently but often with limited adaptability when it comes to interacting with humans. During the past few years, soft robots made of highly pliable materials […]

October 5, 2017 - 5 minutesmins - By External Contributor

News and Trends 4 Oct 2017

Ablynx Launches $175M IPO on Wall Street After Phase III Success

Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […]

October 4, 2017 - 2 minutesmins - By Alex Dale

immatics amgen fundraising cancer immunotherapy

News and Trends 4 Oct 2017

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […]

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

myovant science uterine fibroids treatment

News and Trends 4 Oct 2017

Oral Drug to Treat Uterine Fibroids Boasts Phase III Success

Myovant’s partner Takeda has reported Phase III results showing relugolix to be more effective in treating uterine fibroids than existing hormonal therapy. Myovant has announced positive results from its lead candidate, relugolix, which showed itself to be better than leuprorelin injections — a common first-line treatment — at reducing menstrual bleeding in a Phase III trial in patients […]

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ulf grawunder nbe therapeutics interview

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […]

October 4, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 2 Oct 2017

CRISPR Gets Snubbed Again by the Nobel Prize Committee

The Nobel Prize Committee has made CRISPR wait at least one more year, as it was pipped by research into the mechanisms underlying circadian rhythm. The 2017 Nobel Prize in Physiology or Medicine has been awarded to Jeffrey C. Hall, Michael Rosbash and Michael W. Young. There had been whispers that CRISPR would take home the prize, but the […]

October 2, 2017 - 3 minutesmins - By Alex Dale

More News! 2 Oct 2017

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects

Swedish Gesynta Pharma has signed an agreement with Orexo to acquire a drug candidate to treat inflammatory diseases with fewer side effects. Based in Uppsala, Orexo has built a solid pipeline since its foundation in 1995, including three products currently in the market. The company has now struck a deal for one of its early-stage programs, OX-MPI, focused on inflammation. BI1029539, the […]

October 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Oct 2017

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […]

October 2, 2017 - 3 minutesmins - By Alex Dale

News and Trends 2 Oct 2017

Drugs Can Now be Delivered to Cells On Demand with Light

Cells can be ‘hotwired’ to take up drugs or nanoparticles by endocytosis on demand according to research carried out in the UK. Researchers at Warwick Medical School have found a way to trigger endocytosis in cells. The research, which is published in The Journal of Cell Biology, uses the cell’s own proteins to initiate the endocytosis […]

October 2, 2017 - 3 minutesmins - By Alex Dale

News and Trends 2 Oct 2017

Meet the Young CEO of a PCR Workflow Automation Company

He is a young entrepreneur with a fast growing company. His software for the automation of PCR results interpretation in research laboratories has had a rocket start. Here’s his story! “I was looking for an internship for my bachelor’s degree in computer science…” His story starts like so many others, but unlike most it took […]

October 2, 2017 - 7 minutesmins - By External Contributor

News and Trends 2 Oct 2017

Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe

Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman Stetsyk /Shutterstock

October 2, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Sep 2017

The Art of Darya Warner: Bacterial Portraits, Meaty Tomatoes and Bioluminescence

From beautiful microscopic stills to designing the technology of the future, artist Darya Warner captures the beauty of life in her work. Darya Warner is an artist originally from Belarus, now based in the US, with an eye to spot beauty under the light of the microscope. From genetically engineered fluorescent E. coli to cauliflower, […]

September 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Synbio adds Softness: Robots of the Future will be Squishy

Ablynx Launches $175M IPO on Wall Street After Phase III Success

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Oral Drug to Treat Uterine Fibroids Boasts Phase III Success

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

CRISPR Gets Snubbed Again by the Nobel Prize Committee

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Drugs Can Now be Delivered to Cells On Demand with Light

Meet the Young CEO of a PCR Workflow Automation Company

Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe

The Art of Darya Warner: Bacterial Portraits, Meaty Tomatoes and Bioluminescence

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!